Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05540340 · ClinicalTrials.gov registry record · Phase 1
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
A Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT05540340 is a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 39 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05540340, a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height and weight. The population PK model, tested in this study, uses information based on people who have previously received melphalan and aims to calculate an optimal dose separately for each person. Study researchers think that the dose calculated using the population PK model may still be effective but have less side effects than the standard melphalan dose.
Conditions Studied
Interventions
- OTHER Pharmacokinetics
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-09-09 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05540340
The ClinicalTrials.gov registry entry for NCT05540340 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Pharmacokinetics is the first listed.
NCT05540340 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05540340 about?
NCT05540340 is a clinical study titled "A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant". The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height and weight. The population PK model, tested in this...
What is the current status of trial NCT05540340?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2022-09-09. Estimated completion is 2027-09.
What conditions does trial NCT05540340 study?
This clinical trial studies the following conditions: Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin.
What interventions are being tested in trial NCT05540340?
The interventions under investigation include: Pharmacokinetics (OTHER).
Who is sponsoring clinical trial NCT05540340?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05540340 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.